ES2314747T3 - Nuevos derivados de 2h-cromeno como modulares selectivos de receptores de estrogeno. - Google Patents

Nuevos derivados de 2h-cromeno como modulares selectivos de receptores de estrogeno. Download PDF

Info

Publication number
ES2314747T3
ES2314747T3 ES05824228T ES05824228T ES2314747T3 ES 2314747 T3 ES2314747 T3 ES 2314747T3 ES 05824228 T ES05824228 T ES 05824228T ES 05824228 T ES05824228 T ES 05824228T ES 2314747 T3 ES2314747 T3 ES 2314747T3
Authority
ES
Spain
Prior art keywords
group
alkyl
chromen
ethoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05824228T
Other languages
English (en)
Spanish (es)
Inventor
Nareshkumar F. Jain
Jiayi Xu
Zhihua Sui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2314747T3 publication Critical patent/ES2314747T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES05824228T 2004-11-18 2005-11-17 Nuevos derivados de 2h-cromeno como modulares selectivos de receptores de estrogeno. Expired - Lifetime ES2314747T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62898704P 2004-11-18 2004-11-18
US628987P 2004-11-18

Publications (1)

Publication Number Publication Date
ES2314747T3 true ES2314747T3 (es) 2009-03-16

Family

ID=35883498

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05824228T Expired - Lifetime ES2314747T3 (es) 2004-11-18 2005-11-17 Nuevos derivados de 2h-cromeno como modulares selectivos de receptores de estrogeno.

Country Status (14)

Country Link
US (1) US20060166933A1 (cg-RX-API-DMAC7.html)
EP (1) EP1812417B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008520688A (cg-RX-API-DMAC7.html)
CN (1) CN101103011A (cg-RX-API-DMAC7.html)
AT (1) ATE412643T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005307704A1 (cg-RX-API-DMAC7.html)
CA (1) CA2587669A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005010735D1 (cg-RX-API-DMAC7.html)
DK (1) DK1812417T3 (cg-RX-API-DMAC7.html)
ES (1) ES2314747T3 (cg-RX-API-DMAC7.html)
PL (1) PL1812417T3 (cg-RX-API-DMAC7.html)
PT (1) PT1812417E (cg-RX-API-DMAC7.html)
SI (1) SI1812417T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006055694A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016189011A1 (en) * 2015-05-26 2016-12-01 F. Hoffmann-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
US20200390755A1 (en) * 2018-08-01 2020-12-17 Shaanxi Micot Technology Co., Ltd. Compound for treating nervous system diseases and use thereof
CN119176799B (zh) * 2024-09-19 2025-10-03 晨伫(杭州)生物科技有限责任公司 色烯衍生物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
DE10013782A1 (de) * 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
IL161325A0 (en) * 2001-11-19 2004-09-27 Lilly Co Eli Substituted benzopyrans as selective estrogen receptor-beta agonists
US7329654B2 (en) * 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators

Also Published As

Publication number Publication date
PL1812417T3 (pl) 2009-04-30
SI1812417T1 (sl) 2009-04-30
EP1812417A1 (en) 2007-08-01
CA2587669A1 (en) 2006-05-26
DK1812417T3 (da) 2009-02-16
DE602005010735D1 (de) 2008-12-11
WO2006055694A1 (en) 2006-05-26
JP2008520688A (ja) 2008-06-19
EP1812417B1 (en) 2008-10-29
AU2005307704A1 (en) 2006-05-26
US20060166933A1 (en) 2006-07-27
CN101103011A (zh) 2008-01-09
ATE412643T1 (de) 2008-11-15
PT1812417E (pt) 2008-12-05

Similar Documents

Publication Publication Date Title
ES2366193T3 (es) Nuevos derivados que contienen heteroátomos tetracíclicos útiles como moduladores de receptores de hormonas esteroideas sexuales.
ES2230316T3 (es) Derivados de pirrolopiridinona sustituidos utiles como inhibidores de la fosfodiesterasa.
JP2008528496A (ja) エストロゲン受容体のモジュレーターとして有用な新規な複素環式ベンゾ［ｃ］クロメン誘導体
ES2909234T3 (es) Compuestos de 6-amino-7,9-dihidro-8H-purin-8-ona como inhibidores de Brk
ES2585653T3 (es) Antagonistas del receptor de FSH
ES3029609T3 (en) Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists
ES2379098T3 (es) Derivados de benzopirano novedosos como abridores del canal de potasio
ES2297217T3 (es) Derivados sustituidos de 2,4-dihidro-pirrolo(3,4-b)quinolin-9-ona utilizados como inhibidores de fosfodiesterasa.
US7074779B2 (en) Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
MX2007009784A (es) Compuestos moduladores de receptores de androgenos y metodos.
ES2909709T3 (es) Inhibidores del receptor 2 activado por proteasa
ES2314747T3 (es) Nuevos derivados de 2h-cromeno como modulares selectivos de receptores de estrogeno.
ES2264737T3 (es) Heterocompuestos tetraciclicos como moduladores de receptor de estrogenos.
ES2229319T3 (es) Compuestos benzo(b)tiofeno, intermediarios, procedimientos, composiciones y metodos.
ES2446044T3 (es) Derivados tetracíclicos novedosos que contienen heteroátomos útiles como moduladores de los receptores de hormonas sexuales esteroideas
US8067619B2 (en) Coumarin derivatives as ion channel openers
ES2270129T3 (es) Compuestos heterociclicos del silicio y su utilizacion en el tratamiento de enfermedades o condiciones asociadas a gnrh (hormona liberadora de gonadotropina).
ES2293293T3 (es) Compuestos de organosilicio y su utilizacion.
US20090069362A1 (en) Novel Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors
EP1606307B1 (en) Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
WO2025031504A1 (en) Derivatives and prodrugs of 2, 4-dinitrophenol, and compositions and methods thereof
ES2277118T3 (es) Oxepinas pentaciclicas y sus derivados, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
WO2019040511A1 (en) DOUBLE INHIBITORS OF BCL-2 AND HDM2 FAMILIES BY CO-MIMETTISM OF ALPHA BH3 AND P53 PROPELLERS
EP1778656A1 (en) Benzoxazepine derivatives as selective estrogen receptor modulators